Insurance coverage of Vyzulta expands with Express Scripts

Express Scripts will begin covering Vyzulta under an agreement with Bausch + Lomb, according to a press release.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), indicated for reducing IOP in patients with open-angle glaucoma or ocular hypertension, will be covered under an access position on the commercial Express Scripts National Preferred and Basic formularies, the release said.

“We are proud of this achievement as it signifies the health care community’s recognition of the benefit Vyzulta may offer glaucoma patients,” Tracy Valorie, Bausch + Lomb’s senior vice president and general manager of U.S. Pharmaceuticals and Surgical, said in the release.

Express Scripts will begin covering Vyzulta under an agreement with Bausch + Lomb, according to a press release.

Vyzulta (latanoprostene bunod ophthalmic solution 0.024%), indicated for reducing IOP in patients with open-angle glaucoma or ocular hypertension, will be covered under an access position on the commercial Express Scripts National Preferred and Basic formularies, the release said.

“We are proud of this achievement as it signifies the health care community’s recognition of the benefit Vyzulta may offer glaucoma patients,” Tracy Valorie, Bausch + Lomb’s senior vice president and general manager of U.S. Pharmaceuticals and Surgical, said in the release.